Myriad Genetics (MYGN) Guidance Looks Conservative, Says Goldman Sachs

November 6, 2013 9:27 AM

Goldman Sachs maintained a Neutral rating on Myriad Genetics (NASDAQ: MYGN) and lowered its price target to $31.00 (from $32.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found